Stifel raised the firm’s price target on Regenxbio (RGNX) to $45 from $40 and keeps a Buy rating on the shares as part of a 2026 outlook note for the analyst’s Biopharma coverage.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGNX:
- Regenxbio price target raised to $20 from $16 at Leerink
- RegenXBio’s Strategic Positioning and Advancements Drive Buy Rating Amid Market Opportunities
- RegenXBio’s Gene Therapy Study for Hunter Syndrome: A Potential Game-Changer
- Regenxbio files $300M mixed securities shelf
- RegenXBio’s Strategic Manufacturing and Commercial Readiness Justifies Buy Rating and $34 Price Target